Efficacy of phosphatidylinositol‐3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|9|2234-2242

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.9, 2015-11, pp. : 2234-2242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of the Effects of Two Kinase Inhibitors, Sorafenib and Dasatinib, on Chronic Lymphocytic Leukemia Cells

By  

Oncology Research and Treatment, Vol. 35, Iss. 7-8, 2012-07 ,pp. : 420-426

Karger

Access to resources Recommend Favorite

RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow

By Xu Jingjing   Zhou Peng   Wang Wenjuan   Sun Aining   Guo Feng  

Journal of Molecular Medicine, Vol. 92, Iss. 1, 2014-01 ,pp. : 77-92

Springer Publishing Company

Access to resources Recommend Favorite

LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase

By  

Current Signal Transduction Therapy, Vol. 3, Iss. 2, 2008-05 ,pp. : 129-132

Bentham Science Publishers

Access to resources Recommend Favorite

Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

By  

Acta Haematologica, Vol. 130, Iss. 3, 2013-06 ,pp. : 192-195

Karger

Access to resources Recommend Favorite

Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead

By  

Acta Haematologica, Vol. 136, Iss. 1, 2016-05 ,pp. : 43-44

Karger

Access to resources Recommend Favorite